All In Biotech

Drug Trial Radar · NCT06146088

Lot-to-lot Consistency Study of Three Commercial Batches of Enterovirus 71 Vaccine

To Evaluate the Lot-to-lot Consistency of Immunogenicity, Safety, and Immune Persistence of Three Consecutive Commercial Manufacturing Batches of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell) in Children Aged 6-35 Months in a Randomized, Blinded Study

Last checked: Nov 20, 2026Latest source record: Jan 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,500 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,500

Planned (sponsor's estimate)

Start

Nov 25, 2023

Primary completion

Mar 31, 2024

Study completion Jul 15, 2026

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Centers for Disease Control and Prevention, China
First posted
Nov 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 months, up to 35 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a randomized, blinded study to evaluate the lot-to-lot consistency of immunogenicity, safety, and immune persistence of three consecutive manufacturing lots of EV71 vaccine, in 1500 children aged 6-35 months. The primary immunogenicity endpoint is the anti-EV71 neutralizing antibody geometric mean titer (GMT) 30 days after the final dose. The secondary immunogenicity endpoints are the geometric mean fold increases and seroconversion rates of anti-EV71 neutralizing antibodies 30 days after the final dose. The immune persistence endpoints are the seropositive rates as well as GMT of anti-EV71 neutralizing antibodies 12 and 24 months after the final dose. The safety endpoints are the number of adverse events/reactions within 30 minutes after each dose, the number of solicited adverse events/reactions within 7 days after each dose, the number of unsolicited adverse events/reactions within 30 days after each dose, and the number of serious adverse events (SAE) from the first dose to 6 months post the final dose.

Conditions

  • Hand, Foot and Mouth Disease

Interventions

  • EV71 VaccineBiological

    Inactivated enterovirus 71 vaccine (human diploid cell) of 3.0EU/0.5mL on Day 0,30

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Immunogenicity index-geometric mean titer (GMT) of neutralizing antibodyTime frame: Day 30 after the second vaccination

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Chencang Center for Disease Prevention and Control

    Baoji, Shaan XI, China · Not yet recruiting

  • Ningqiang Center for Disease Prevention and Control

    Hanzhong, Shaan XI, China · Recruiting

  • Fuping Center for Disease Prevention and Control

    Weinan, Shaan XI, China · Not yet recruiting

  • Jingyang Center for Disease Prevention and Control

    Xianyang, Shaan XI, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.